Joachim Almquist

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Rheumatoid Arthritis Patients

Top Venues

Clinical pharmacokinetics

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Philip Ambery, Grzegorz Zajac, Joachim Almquist, Susanne Prothon, Carol Astbury, Mary N Brown, Szilárd Nemes, Joselyne Nsabimana, Karl Edman, Lisa Öberg, Matti Lepistö, Goran Edenro, Inken Dillmann, Suman Mitra, Graham Belfield, Christina Keen, Tim Heise
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial. British journal of clinical pharmacology (2024)
Philip Ambery, Grzegorz Zajac, Joachim Almquist, Susanne Prothon, Carol Astbury, Mary N Brown, Szilárd Nemes, Joselyne Nsabimana, Karl Edman, Lisa Öberg, Matti Lepistö, Goran Edenro, Inken Dillmann, Suman Mitra, Graham Belfield, Christina Keen, Tim Heise
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial. British journal of clinical pharmacology 90 (8) (2024)
Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I White, David W Boulton, Alexander MacDonald
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical pharmacokinetics 62 (5) (2023)
Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I White, David W Boulton, Alexander MacDonald
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical pharmacokinetics 62 (5) (2023)
Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I White, David W Boulton, Alexander MacDonald
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical pharmacokinetics (2023)
Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I White, David W Boulton, Alexander MacDonald
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical pharmacokinetics 62 (5) (2023)